Eli Lilly rises 6%; company raises 2024 sales forecast by $2 billion

Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 6%.